- Home
- NDP vs PLX Comparison
NDP vs PLX Comparison
Compare NDP & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDP
- PLX
- Stock Information
- Founded
- NDP 2005
- PLX 1993
- Country
- NDP United States
- PLX Israel
- Employees
- NDP N/A
- PLX N/A
- Industry
- NDP Finance/Investors Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NDP Finance
- PLX Health Care
- Exchange
- NDP Nasdaq
- PLX Nasdaq
- Market Cap
- NDP 71.4M
- PLX 79.4M
- IPO Year
- NDP N/A
- PLX 1998
- Fundamental
- Price
- NDP $43.09
- PLX $1.39
- Analyst Decision
- NDP
- PLX
- Analyst Count
- NDP 0
- PLX 0
- Target Price
- NDP N/A
- PLX N/A
- AVG Volume (30 Days)
- NDP 6.1K
- PLX 310.7K
- Earning Date
- NDP 01-01-0001
- PLX 11-14-2024
- Dividend Yield
- NDP 7.54%
- PLX N/A
- EPS Growth
- NDP N/A
- PLX N/A
- EPS
- NDP N/A
- PLX N/A
- Revenue
- NDP N/A
- PLX $45,667,000.00
- Revenue This Year
- NDP N/A
- PLX N/A
- Revenue Next Year
- NDP N/A
- PLX $88.94
- P/E Ratio
- NDP N/A
- PLX N/A
- Revenue Growth
- NDP N/A
- PLX N/A
- 52 Week Low
- NDP $26.46
- PLX $0.82
- 52 Week High
- NDP $33.43
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- NDP 76.93
- PLX 66.10
- Support Level
- NDP $42.54
- PLX $1.14
- Resistance Level
- NDP $43.02
- PLX $1.34
- Average True Range (ATR)
- NDP 0.40
- PLX 0.07
- MACD
- NDP 0.28
- PLX 0.02
- Stochastic Oscillator
- NDP 99.55
- PLX 92.59
About NDP Tortoise Energy Independence Fund Inc.
Tortoise Energy Independence Fund, Inc. is a non-diversified closed-end management investment company. Its primary investment objective to seek a high level of total return with an emphasis on current distributions. The fund invests primarily in equity securities of upstream North American energy companies that engage in the exploration and production of crude oil, condensate, natural gas and natural gas liquids that generally have a presence in North American oil and gas fields, including shale reservoirs.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.